Astellas Plans to Wind Down ADC ResearchBy
As part of a move to refine its oncology strategy by expanding its investment in new technologies and modalities and reducing its focus on antibody drug conjugate (ADC) research, Astellas Pharma plans to is wind down its Agensys research operations in Santa Monica, California.
Astellas will continue certain clinical trials and collaborations on ADC programs that have been in progress at Agensys, including its collaboration with the Seattle-based biotechnology company, Seattle Genetics.
Astellas plans to complete the wind-down of Agensys research operations in the first quarter of calendar 2018. Astellas is still reviewing the impact of this development on its financial forecasts for the fiscal year ending March 31, 2018.
Source: Astellas Pharma